Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15051 - 15075 of 15154 in total
4SC-203 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
Experimental
Investigational
Hydroxypropyl betadex is under investigation in clinical trial NCT03471143 (Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C).
Investigational
Matched Iupac: … -5,10,25,35-tetrakis(hydroxymethyl)-40,47,49-tris(2-hydroxypropoxy)-15,20,30-tris[(2-hydroxypropoxy)methyl
Experimental
Vet approved
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and
Experimental
Experimental
Investigational
Matched Iupac: … 36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-35-(hydroxymethyl)-10,15,20,25,30-pentakis[(4-sulfonatobutoxy)methyl
Siagoside (Sygen, AGF 2) has been investigated for the treatment of Parkinson Disease. It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and repair. Siagoside completed phase 2 trials for parkinson's disease (PD) treatment. Sygen appears to...
Investigational
Matched Description: … substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and
This compound belongs to the nitrofurans. These are compounds containing a furan ring which bears a nitro group. It targets the protein aldose reductase.
Experimental
Experimental
Matched Iupac: … dihydroxy-6-(hydroxymethyl)-5-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}methyl
LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism...
Investigational
Matched Description: … of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and
Displaying drugs 15051 - 15075 of 15154 in total